via University of Houston
Breathe in, breathe out. That’s how easy it is for SARS-CoV-2, the virus that causes COVID-19, to enter your nose. And though remarkable progress has been made in developing intramuscular vaccines against SARS-CoV- 2, such as the readily available Pfizer, Moderna and Johnson & Johnson vaccines, nothing yet – like a nasal vaccine – has been approved to provide mucosal immunity in the nose, the first barrier against the virus before it travels down to the lungs.
But now, we’re one step closer.
Navin Varadarajan, University of Houston M.D. Anderson Professor of Chemical and Biomolecular Engineering, and his colleagues, are reporting in iScience the development of an intranasal subunit vaccine that provides durable local immunity against inhaled pathogens.
“Mucosal vaccination can stimulate both systemic and mucosal immunity and has the advantagggggggggge of being a non-invasive procedure suitable for immunization of large populations,” said Varadarajan. “However, mucosal vaccination has been hampered by the lack of efficient delivery of the antigen and the need for appropriate adjuvants that can stimulate a robust immune response without toxicity.”
“Our results show that the candidate vaccine formulation is safe, produces rapid immune responses – within seven days – and elicits comprehensive immunity against SARS-CoV-2.”Navin Varadarajan, lead study author
To solve those problems, Varadarajan collaborated with Xinli Liu, associate professor of pharmaceutics at the UH College of Pharmacy, and an expert in nanoparticle delivery. Liu’s team was able to encapsulate the agonist of the stimulator of interferon genes (STING) within liposomal particles to yield the adjuvant named NanoSTING. The function of the adjuvant is to promote the body’s immune response.
“NanoSTING has a small particle size around 100 nanometers which exhibits significantly different physical and chemical properties to the conventional adjuvant,” said Liu.
“We used NanoSTING as the adjuvant for intranasal vaccination and single-cell RNA-sequencing to confirm the nasal-associated lymphoid tissue as an inductive site upon vaccination. Our results show that the candidate vaccine formulation is safe, produces rapid immune responses – within seven days – and elicits comprehensive immunity against SARS-CoV-2,” said Varadarajan.
“Equitable distribution requires vaccines that are stable and that can be shipped easily.”
A fundamental limitation of intramuscular vaccines is that they are not designed to elicit mucosal immunity. As prior work with other respiratory pathogens like influenza has shown, sterilizing immunity to virus re-infection requires adaptive immune responses in the respiratory tract and the lung.
The nasal vaccine will also serve to equitably distribute vaccines worldwide, according to the researchers. It is estimated that first world countries have already secured and vaccinated multiple intramuscular doses for each citizen while billions of people in countries like India, South Africa, and Brazil with large outbreaks are currently not immunized. These outbreaks and viral spread are known to facilitate viral evolution leading to decreased efficacy of all vaccines.
“Equitable distribution requires vaccines that are stable and that can be shipped easily. As we have shown, each of our components, the protein (lyophilized) and the adjuvant (NanoSTING) are stable for over 11 months and can be stored and shipped without the need for freezing,” said Varadarajan.
Varadarajan is co-founder of AuraVax Therapeutics Inc., a pioneering biotech company developing novel intranasal vaccines and therapies to help patients defeat debilitating diseases, including COVID-19. The company has an exclusive license agreement with UH with respect to the intellectual property covering intranasal vaccines and STING agonist technologies. They have initiated the manufacturing process and plan to engage the FDA later this year.
Original Article: IN THROUGH THE NOSE…
More from: University of Houston | University of Texas MD Anderson Cancer Center
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Intranasal Vaccines: A Potential Off-Ramp For Coronavirus Pandemicson June 1, 2023 at 5:00 pm
This is where the current batch of commonly used SARS-CoV-2 vaccines are showing a major issue, as they do not provide significant immunity in the nasal passage’s mucosal tissues, even though ...
- Ketamine nasal spray may help treat migraine, study suggestson May 30, 2023 at 3:30 pm
May 30 (UPI) -- Ketamine nasal spray may be effective in treating chronic migraines, according to a new study.
- Participate in a COVID intranasal vaccine studyon May 29, 2023 at 5:00 pm
The Johns Hopkins CIR is looking for healthy volunteers to participate in an outpatient COVID-19 intranasal vaccine study. If you are between the ages of 18 and 50, you may be eligible to participate.
- An alternative to fertilized chicken egg influenza vaccine productionon May 28, 2023 at 11:31 pm
Current influenza vaccines are produced in fertilized chicken eggs, while this has proven to be efficacious and safe, there are numerous drawbacks. As such, cell-based manufacturing is proving an ...
- Virtually ouch-free: Promising early data on a measles vaccine delivered via stickeron May 26, 2023 at 7:19 am
Vaccine experts are excited about new clinical trial results for a device that delivers measles vaccine via a "microarray" patch — no syringe needed.
Go deeper with Google Headlines on:
[google_news title=”” keyword=”nasal vaccine” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
- Oral Vaccine Delivery: Can it Protect Against Non-mucosal Pathogens?on June 1, 2023 at 5:00 pm
The possibility of developing oral vaccines against non-mucosal pathogens is supported by studies with Japanese encephalitis and hepatitis B, which are transmitted by mosquito- and blood-borne ...
- Elanco to distribute Aptimmune's PRRS killed autogenous vaccineon May 31, 2023 at 6:23 am
Porcine reproductive and respiratory syndrome cost the U.S. swine industry $664 million per year from 2005 to 2010, or about $1.8 million per day.
- Research Warn Of High Risk For Mpox Resurgence This Summer As Vaccine Immunity Waneson May 28, 2023 at 6:11 pm
The World Health Organization today declared an end to the mpox public health emergency. But just two days earlier, the Chicago Department of Public Health (CDPH) announced a potential resurgence of ...
- National-level comprehensive mapping of high-fatality SARS-CoV-2 outbreaks in nursing homeson May 24, 2023 at 2:52 am
In a recent study published in the Nature Aging Journal, researchers analyzed data from three SARS-CoV-2 outbreaks among nursing homes in Belgium with high case-fatality ratios (CFRs, 209 to 35%) to ...
- White House Pushes to Save Key Covid Programs in Debt Ceiling Talkson May 23, 2023 at 3:15 pm
The Biden administration has prioritized preserving a $5 billion vaccine development program in discussions with House Republicans on clawing back unspent Covid-19 funds.
Go deeper with Google Headlines on:
[google_news title=”” keyword=”mucosal vaccination” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]